Back in 2009, the International Association for the Study of Lung Cancer presented a model they’d developed to help stage malignant mesothelioma cases. Since then, additional data has been added to the model’s database to continue enhancing its accuracy. This week, the group’s members attending its annual conference in Singapore learned that the model is
Dr. Stephen Liu is a hematologist and oncologist at MedStar Georgetown University Hospital. He focuses on thoracic malignancies, including lung cancer, thymic malignancies, and pleural mesothelioma. He has significant expertise in the development of novel therapeutic agents and in combining treatment protocols with the goal of improving patient outcomes. Education and Career Dr. Liu graduated
Dr. Frank Detterbeck is a thoracic surgeon, board-certified in general surgery as well as in thoracic and cardiac surgery. As a surgeon at the Yale Cancer Center, he has earned a national reputation for performing minimally invasive surgeries for the treatment of lung cancer, mesothelioma, and other thoracic malignancies. Education and Career Dr. Detterbeck earned
Dr. Roy Herbst is an internationally recognized clinician-scientist who has dedicated himself to thoracic cancer treatment and research. He is a leader in the treatment of lung cancer and is renowned for his work in developmental therapeutics and personalized therapies that link the individual patient’s genetic profile to the treatment offered. Education and Career Dr.
Identifying the right treatment plan is one of the many challenges faced by mesothelioma patients and their physicians. Those whose tumors are operable need to decide whether to pursue an aggressive form of surgery that removes the affected lung or to go with a less invasive procedure. A report issued today suggests that those who
Dr. John D. Mitchell is the Chief of General Thoracic Surgery within the Division of Cardiothoracic Surgery at the University of Colorado and the CU Cancer Center. He has extensive experience in treating thoracic cancers, including pleural mesothelioma. His practice specialties include all areas of thoracic oncology and surgery of the airway, with a special
Dr. Camidge is a thoracic oncologist at the University of Colorado. He has been the Director of CU’s Thoracic Oncology Clinical Program and Clinical Research Program since 2007. His approach to treating pleural mesothelioma and lung cancer focuses on a personalized approach in which treatment plans are based on the results of specific tests to
Because asbestos has been used all over the world, malignant pleural mesothelioma has become a global problem. The search for effective treatments is being conducted all over the world, and researchers from the Hyogo College of Medicine recently shared positive results from a study of an inhalable gene therapy.
Robotic surgery represents one of the most innovative breakthroughs for treating patients with malignant pleural mesothelioma. Its development has provided new options for patients whose tumors were so inaccessible that they would previously have been referred for palliative care. In the skilled hands of some of the world’s most accomplished thoracic surgeons, minimally invasive robotic
Dr. Anthony W. Kim is an internationally respected thoracic surgeon and oncologist. He leads the thoracic surgery division and program at Keck Medicine of the University of Southern California. He treats patients with thoracic cancers, including pleural mesothelioma and lung cancer, and specializes in minimally invasive surgery, including both thoracoscopic and robotic surgery. Education and